Transthyretin

Transthyretin Molekülinformation

Englischer Name	Transthyretin	Anzahl der inverkehr gebrachten Arzneimittel	7
Anzahl der klinischen Arzneimittel	8	Target-Alias	TTR，Transthyretin，Prealbumin， Amyloidosis Type I，PALB，ATTR，TBPA，Epididymis Luminal Protein 111，Thyroxine-Binding Prealbumin，Carpal Tunnel Syndrome 1，Prealbumin，HsT2651，HEL111，CTS1，CTS
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Transthyretin
Target-Alias	TTR，Transthyretin，Prealbumin， Amyloidosis Type I，PALB，ATTR，TBPA，Epididymis Luminal Protein 111，Thyroxine-Binding Prealbumin，Carpal Tunnel Syndrome 1，Prealbumin，HsT2651，HEL111，CTS1，CTS
Anzahl der inverkehr gebrachten Arzneimittel	7
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Approved

Transthyretin Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TTR-H5223	Human	HEK293	Human Transthyretin / Prealbumin Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

Transthyretin Molekülhintergrund

Transthyretin (TTR) is also known as Prealbumin, ATTR, TBPA, PALB, which belongs to the transthyretin family. Transthyretin / TTR is a serum and cerebrospinal fluid carrier of the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol. In cerebrospinal fluid TTR is the primary carrier of T4. TTR also acts as a carrier of retinol (vitamin A) through its association with retinol-binding protein (RBP) in the blood and the CSF. Less than 1% of TTR's T4 binding sites are occupied in blood. TTR misfolding and aggregation is known to be associated with the amyloid diseases.

Transthyretin Molekülalias

Transthyretin,TTR,Prealbumin,TBPA,ATTR,PALB,CTS,CTS1,HsT2651

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Nucresiran	ALNTTRsc-04	Phase 3 Clinical	Alnylam Pharmaceuticals Inc	Cardiomyopathies; Transthyretin amyloidosis	Details
Florbetaben	LNTH-2515	Phase 3 Clinical	Arcus Biosciences Inc	Immunoglobulin Light-chain Amyloidosis; Transthyretin amyloidosis	Details
Cliramitug	ALXN2220; ALXN-2220; NI006; NI-006	Phase 3 Clinical	Neurimmune Ag	Cardiomyopathies; Transthyretin amyloidosis	Details
Coramitug	NNC6019-0001; NNC-6019; PRX-004; NN6019	Phase 3 Clinical	Novo Nordisk A/S	Cardiomyopathies; Transthyretin amyloidosis	Details
Nexiguran ziclumeran	NTLA-2001	Phase 3 Clinical	Intellia Therapeutics Inc	Amyloid Neuropathies; Amyloid Neuropathies, Familial; Amyloidosis; Amyloidosis, Familial; Cardiomyopathies; Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Metabolic Diseases; Metabolism, Inborn Errors; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases; Polyneuropathies; Transthyretin amyloidosis	Details
ART-001	ART-001; ART001	Phase 2 Clinical	Ruizheng Gene (Suzhou) Co Ltd	Cardiomyopathies; Transthyretin amyloidosis	Details
YOLT-201	YOLT-201	Phase 2 Clinical	Shanghai Yaotang Biotechnology Co Ltd	Cardiomyopathies; Genetic Diseases, Inborn; Polyneuropathies; Transthyretin amyloidosis	Details
BPR-30221616	BPR-30221616; BPR30221616	Phase 1 Clinical	Chengdu Brilliant Pharmaceutical Co Ltd	Cardiomyopathies; Transthyretin amyloidosis	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Patisiran	SAR-438037; GENZ-438027; ALN-TTR02; ALN-18328	Approved	Alnylam Pharmaceuticals Inc	Onpattro	United States	Amyloid Neuropathies, Familial	Alnylam Pharmaceuticals Inc	2018-08-10	Amyloid Neuropathies; Amyloid Neuropathies, Familial; Amyloidosis; Amyloidosis, Familial; Cardiomyopathies; Polyneuropathies; Transthyretin amyloidosis	Details
Vutrisiran sodium	ALN-TTRSC02; ALN‑TTRsc02; ALN‑65492; AD-65492	Approved	Alnylam Pharmaceuticals Inc	AMVUTTRA	United States	Amyloid Neuropathies, Familial; Transthyretin amyloidosis	Alnylam Pharmaceuticals Inc	2022-06-13	Amyloid Neuropathies, Familial; Amyloidosis, Familial; Cardiomyopathies; Transthyretin amyloidosis	Details
Acoramidis Hydrochloride	BBP-265; AG-10; ALXN-2060; ALXN 2060	Approved	Stanford University	Attruby, Beyonttra	United States	Transthyretin amyloidosis	Bridgebio Pharma Inc	2024-11-22	Amyloid Neuropathies; Amyloid Neuropathies, Familial; Amyloidosis; Amyloidosis, Familial; Cardiomyopathies; Heart Diseases; Polyneuropathies; Transthyretin amyloidosis	Details
Inotersen sodium	ISIS-420915; GSK-2998728	Approved	Ionis Pharmaceuticals Inc	Tegsedi	EU	Amyloidosis	Akcea Therapeutics Ireland Ltd	2018-07-05	Adenomatous Polyposis Coli; Amyloid Neuropathies, Familial; Amyloidosis; Transthyretin amyloidosis	Details
Tafamidis	PF-6291826; Fx-1006A; PF-06291826; FX-1006A	Approved	Pfizer Inc	维万心, VYNDAMAX	United States	Heart Diseases	Foldrx Pharmaceuticals Inc	2019-05-03	Heart Diseases; Transthyretin amyloidosis	Details
Eplontersen	IONIS-TTR-LRx; AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx	Approved	Ionis Pharmaceuticals Inc	WAINUA, 万诺维	United States	Transthyretin amyloidosis	Astrazeneca Ab	2023-12-21	Amyloid Neuropathies, Familial; Cardiomyopathies; Transthyretin amyloidosis	Details
Tafamidis Meglumine	FX-1006A; PF-6291826; Fx-1006A; PF-06291826	Approved	Pfizer Inc	维达全, Vyndaqel	EU	Amyloidosis	Pfizer Europe Ma Eeig	2011-11-16	Amyloid Neuropathies; Amyloid Neuropathies, Familial; Amyloidosis; Cardiomyopathies; Immunoglobulin Light-chain Amyloidosis; Transthyretin amyloidosis	Details